Anavex Life Sciences (NASDAQ:AVXL) and ALGAE TEC LTD/S (OTCMKTS:ALGXY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
This is a breakdown of recent recommendations and price targets for Anavex Life Sciences and ALGAE TEC LTD/S, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences||0||0||4||0||3.00|
|ALGAE TEC LTD/S||0||0||0||0||N/A|
Valuation & Earnings
This table compares Anavex Life Sciences and ALGAE TEC LTD/S’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anavex Life Sciences||N/A||N/A||-$13.46 million||($0.33)||-7.73|
|ALGAE TEC LTD/S||$2.05 million||1.54||-$6.08 million||N/A||N/A|
ALGAE TEC LTD/S has higher revenue and earnings than Anavex Life Sciences.
This table compares Anavex Life Sciences and ALGAE TEC LTD/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences||N/A||-70.18%||-61.79%|
|ALGAE TEC LTD/S||N/A||N/A||N/A|
Insider & Institutional Ownership
20.0% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 0.1% of ALGAE TEC LTD/S shares are held by institutional investors. 12.1% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Anavex Life Sciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, ALGAE TEC LTD/S has a beta of 92.6, suggesting that its stock price is 9,160% more volatile than the S&P 500.
ALGAE TEC LTD/S beats Anavex Life Sciences on 5 of the 9 factors compared between the two stocks.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. Its preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.
ALGAE TEC LTD/S Company Profile
Affinity Energy and Health Limited produces and sells algal oil and biomass primarily to the nutraceutical market in Australia, India, and the United States. It offers algae products, such as proteins for consumption; and biofuel oils for the transportation and power generation. The company was founded in 2007 and is based in Perth, Australia.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.